clinical trial · NCT04482595
BIO 300 Oral Suspension in Previously Hospitalized Long COVID Patients
COVID-19Long COVIDPulmonary FibrosisPost-acute Respiratory Complications of COVID-19BIO 300 Oral SuspensionPlacebo
brief summary
This is a randomized, double-blinded, placebo-controlled, two-arm study to evaluate the safety and efficacy of BIO 300 Oral Suspension (BIO 300) as a therapy to improve lung function in patients that were hospitalized for severe COVID-19-related illness and continue to experience post-acute respiratory complications associated with Long-COVID after discharge. Patients will be randomized 1:1 to receive BIO 300 or placebo.
started
Nov 11, 2020
primary completion
Jul 31, 2024
completion
Apr 30, 2025
last updated
Oct 1, 2024
official title
A Phase 2 Study of BIO 300 Oral Suspension in Discharged COVID-19 Patients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol